Last updated on April 2019

Study of Pharmacodynamics Pharmacokinetics Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Brief description of study

This study will investigate the safety and efficacy of VAY736 administered subcutaneously (s.c.) every 4 weeks for 48 weeks. Approximately, 84 subjects will be randomized in a 1:1 ratio on top of local standard of care (SOC), to receive VAY736 or placebo.

Clinical Study Identifier: NCT03287414

Find a site near you

Start Over

Novartis Investigative Site

Bobigny cedex, France
  Connect »